Biosensors and Bioelectronics Cell-Based Biosensors: Recent
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Biosensors and Bioelectronics 142 (2019) 111530
Biosensors and Bioelectronics 142 (2019) 111530 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: www.elsevier.com/locate/bios Highly sensitive bioaffinity electrochemiluminescence sensors: Recent T advances and future directions ∗ Bahareh Babamiria,b, Delnia Baharia,b, Abdollah Salimia,b,c, a Department of Chemistry, University of Kurdistan, 66177-15175, Sanandaj, Iran b Research Center for Nanotechnology, University of Kurdistan, 66177-15175, Sanandaj, Iran c Department of Chemistry, University of Western Ontario, N6A 5B7, London, Ontario, Canada ARTICLE INFO ABSTRACT Keywords: Electrogenerated chemiluminescence (also called electrochemiluminescence and abbreviated ECL) has attracted Electrochemiluminescence much attention in various fields of analysis due to the potential remarkably high sensitivity, extremely wide Bioaffinity sensors dynamic range and excellent controllability. Electrochemiluminescence biosensor, by taking the advantage of Aptasensor the selectivity of the biological recognition elements and the high sensitivity of ECL technique was applied as a Immunoassays powerful analytical device for ultrasensitive detection of biomolecule. In this review, we summarize the latest Genosensor sensing applications of ECL bioanalysis in the field of bio affinity ECL sensors including aptasensors, im- Cytosensor Medical diagnostics munoassays and DNA analysis, cytosensor, molecularly imprinted sensors, ECL resonance energy transfer and Nanomaterials ratiometric biosensors and give future perspectives for new developments in ECL analytical technology. Furthermore, the results herein discussed would demonstrate that the use of nanomaterials with unique chemical and physical properties in the ECL biosensing systems is one of the most interesting research lines for the development of ultrasensitive electrochemiluminescence biosensors. In addition, ECL based sensing assays for clinical samples analysis and medical diagnostics and developing of immunosensors, aptasensors and cytosensor for this purpose is also highlighted. -
Accomplishments in Nanotechnology
U.S. Department of Commerce Carlos M. Gutierrez, Secretaiy Technology Administration Robert Cresanti, Under Secretaiy of Commerce for Technology National Institute ofStandards and Technolog}' William Jeffrey, Director Certain commercial entities, equipment, or materials may be identified in this document in order to describe an experimental procedure or concept adequately. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment used are necessarily the best available for the purpose. National Institute of Standards and Technology Special Publication 1052 Natl. Inst. Stand. Technol. Spec. Publ. 1052, 186 pages (August 2006) CODEN: NSPUE2 NIST Special Publication 1052 Accomplishments in Nanoteciinology Compiled and Edited by: Michael T. Postek, Assistant to the Director for Nanotechnology, Manufacturing Engineering Laboratory Joseph Kopanski, Program Office and David Wollman, Electronics and Electrical Engineering Laboratory U. S. Department of Commerce Technology Administration National Institute of Standards and Technology Gaithersburg, MD 20899 August 2006 National Institute of Standards and Teclinology • Technology Administration • U.S. Department of Commerce Acknowledgments Thanks go to the NIST technical staff for providing the information outlined on this report. Each of the investigators is identified with their contribution. Contact information can be obtained by going to: http ://www. nist.gov Acknowledged as well, -
Sensors 2010, 10, 6796-6820; Doi:10.3390/S100706796 OPEN ACCESS Sensors ISSN 1424-8220
Sensors 2010, 10, 6796-6820; doi:10.3390/s100706796 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review Intelligent Chiral Sensing Based on Supramolecular and Interfacial Concepts Katsuhiko Ariga 1,2,*, Gary J. Richards 1, Shinsuke Ishihara 1, Hironori Izawa 1,2 and Jonathan P. Hill 1,2 1 World Premier International (WPI) Research Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba 305-0044, Japan 2 Japan Science and Technology Agency, CREST, 1-1 Namiki, Tsukuba 305-0044, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-29-860-4597; Fax: +81-29-860-4832. Received: 17 June 2010; in revised form: 7 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010 Abstract: Of the known intelligently-operating systems, the majority can undoubtedly be classed as being of biological origin. One of the notable differences between biological and artificial systems is the important fact that biological materials consist mostly of chiral molecules. While most biochemical processes routinely discriminate chiral molecules, differentiation between chiral molecules in artificial systems is currently one of the challenging subjects in the field of molecular recognition. Therefore, one of the important challenges for intelligent man-made sensors is to prepare a sensing system that can discriminate chiral molecules. Because intermolecular interactions and detection at surfaces are respectively parts of supramolecular chemistry -
Biopharmaceutical Sector Update: Market Outlook for 2021
Biopharmaceutical Sector Update Market Outlook for 2021 January 11, 2021 © 2021. All rights reserved. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. Table of Contents An Extraordinary Year: Top 10 Biopharma Events of 2020 4 Biopharma Sector Outlook for 2021 20 The Evolving World of Biotech Company Formation 26 Implications of the U.S. Election on the Biopharma Sector 31 Update on Covid-19, Capital Markets and M&A Activity 39 About Torreya 50 Key Topics in This Update In this report we discuss three topics that are front of mind in our industry: We have lived through an Given the exceptional performance of the biopharma extraordinary year for the #1 market in 2020, what does 2021 hold? biopharmaceutical industry. Given excellent protection data on two COVID-19 vaccines we now appear It appears likely that with widespread vaccination, #2 the COVID-19 pandemic will recede in 2021. What to be at the beginning of the end of does this imply for the biopharma sector? the COVID-19 pandemic. A “return to normalcy” appears possible in 2021 despite a very challenging situation What are the implications of the U.S. political #3 situation for the global biopharmaceutical sector? at present with the pandemic. 3 An Extraordinary Year: Top 10 Biopharma Events of 2020 4 Event #1 COVID-19 Vaccines Portend a New Normal The FDA has approved two COVID-19 vaccines as of Jan 2021 and more vaccine approvals are likely. -
Biosensor Laboratory Selected Publications 1. Irina Sorokulova
Biosensor Laboratory Selected Publications 1. Irina Sorokulova, Eric Olsen, Vitaly Vodyanoy, Bacteriophage biosensors for antibiotic resistant bacteria. Expert Rev Med Devices. 2014 Mar;11(2):175-86. doi: 10.1586/17434440.2014.882767. 2. I.Sorokulova, R. Guntupalli, E. Olsen, L. Globa, O. Pustovyy, V. Vodyanoy. Lytic Phage in Biosensing, ECS Transactions, 58 (23) 1-7 (2014) 10.1149/05823.000lecst ©The Electrochemical Society. 3. Jia, H, Pustovyy, OM, Waggoner, P, Beyers, RJ, Schumacher, J, Wildey, C, Barrett, J, Morrison, E, Salibi, N, Denney, TS, Vodyanoy, VJ, Deshpande, G. Functional MRI of the olfactory system in conscious dogs. PLoS One, 9:e86362 (2014). 4. Kyathanahally SP, Jia H, Pustovyy OM, Waggoner P, Beyers R, Schumacher J, Barrett J, Morrison EE, Salibi N, Denney TS, Vodyanoy VJ, Deshpande G. 2014. Anterior- posterior dissociation of the default mode network in dogs. Brain structure & function: 1- 14. 5. Moore T, Globa L, Barbaree J., Vodyanoy V., Sorokulova I. Antagonistic Activity of Bacillus Bacteria against Food-Borne Pathogens. Journal of Probiotics and Health. Vol. 1(3): 1-6 (2013) 6. Vitaly J. Vodyanoy, Yuri Mnyukh, The Physical Nature of "Giant" Magnetocaloric and Electrocaloric Effects, American Journal of Materials Science, Vol. 3 No. 5, 2013, pp. 105-109. doi: 10.5923/j.materials.20130305.01. 7. Moore T, Sorokulova I, Pustovyy O, Globa L, Vodyanoy V (2013). Microscopic evaluation of vesicles shed by rat erythrocytes at elevated temperatures. Journal of Thermal Biology, 38:487-492. 8. Moore T, Sorokulova I, Pustovyy O, Globa L, Pascoe D, Rudisill M, Vodyanoy V. (2013) Microscopic evaluation of vesicles shed by erythrocytes at elevated temperatures. -
The Future for Biosensors in Biopharmaceutical Production
Pharmaceutical Commentary BRACEWELL & POLIZZI The future for biosensors in biopharmaceutical production 2 Commentary The future for biosensors in biopharmaceutical production Pharm. Bioprocess. Keywords: bioprocess monitoring • bioprocess control • in-vivo biosensor • PAT Daniel G Bracewell*,1 • synthetic biology & Karen M Polizzi2 1The Advanced Centre for Biochemical Engineering, Department of Biochemical A defining feature of bioprocesses is the need straightforward. This is not to say there have Engineering, University College London, for measurement, monitoring and control; in not been significant successes: Torrington Place, London, WC1E 7JE, UK the context of biopharmaceuticals this need 2Department of Life Sciences & Centre • The world’s diabetic population depends is further heightened by the absolute require- for Synthetic Biology & Innovation, on blood glucose measurements to admin- Imperial College London, London, UK ment to ensure the quality of the product [1] . ister insulin based on an amperometric *Author for correspondence: This is evidenced by the size of bioanalytical based biosensor technology (enzyme elec- [email protected] endeavor found within the R&D programs trodes). This represents the largest single of the major biopharmaceutical companies biosensor application in terms of numbers and the supplier industry that caters for this of devices and market size; instrumentation need. It is a need that grows at a pace reflected in the initiatives involv- • Optical biosensors, largely surface plas- ing the regulatory authorities such as PAT mon resonance (BIAcore) has become central to the larger vision of QbD. At the the default method to directly mea- core of these attempts to improve biophar- sure protein–protein interactions in the maceutical production is the need for rapid, laboratory. -
Biopharmaceutical Notes
An Overview of the BioPharmaceutical Products and Market By Paul DiMarco, Vice President, Global Commercial Program, BioSpectra Inc. Table of Contents INTRODUCTION: ........................................................................................................................................ 2 History ....................................................................................................................................................... 2 Background information ........................................................................................................................... 3 Defining biological products ..................................................................................................................... 4 Small vs. Large Molecule Regulation and Registration in the USA and EU ............................................... 6 Controversial Regulatory Concepts: ......................................................................................................... 7 Extrapolation: ........................................................................................................................................ 7 Switching: .............................................................................................................................................. 8 Interchangeability: ................................................................................................................................ 9 Harmonization: .................................................................................................................................... -
Bioelectronics Contents
chapter 10 Bioelectronics Contents Introduction . 253 Biosensors. 253 Biochips. 254 Priorities for Future Research . 256 Chapter IO References . 256 Figure Figure No. Page 29.The Use of Proteins in Constructing Circuit . ..., . 255 — Chapter 10 Bioelectronics .—— .— Introduction --—----- ——— The potential for the use of proteins in elec- used for several years, but design problems have tronic dmices has received attention recently with limited their acceptance. Biotechnology is ex- the advent of recombinant DNA (rDNA) technol- pected to increase the variety, stability, and sen- ogy}’ and the potential for computer-aided design sitivity of these devices. Biochips (biologically of proteins (I ,2,3 5 ,6,7, 11, 13,14,15,19,2 1 ). Work based microchips) capable of logic and memory is focused in two areas: biosensors and biochips. are still only speculative, and their development Biosensors (biological}’ based sensors) have been is many years away. Biosensors -——-- –—- —— .——. A potential application of biotechnology is in the not only could obviate the need for enzymes but development of improved sensing devices. Be- also could substantially broaden the applications cause of their high specificity. for given sub- of biosensors. A longer term solution to the lack of stances, enzymes and monocIonal antibodies particular enzymes might be to have computers (hlAbs) are particularly suited for use as sensors. design enzymes with particular catalytic func- Sensors using these biological molecules have the tions. Finally, features of proteins that determine potential to be smaller and more sensitive than temperature stability could be incorporated into traditional sensors. the genes that code for important sensing en- zymes. Biosensors using enzymes have been used to detect the presence of various organic compounds A new approach to fabrication is yielding bio- for many years (12). -
Advances in BIOPHARMACEUTICAL TECHNOLOGY in CHINA New Second Edition!
Establish China partnerships Create Effective Strategies to EXPAND YOUR GLOBAL REACH! Advances in BIOPHARMACEUTICAL TECHNOLOGY in CHINA New Second Edition! A great opportunity exists in working with Chinese companies to establish scientific and business partnerships, and to create effective strategies. However, success in Asia in the new millennium will require changes in partnerships between Western and Asian companies. Every company faces the question “What should our China strategy be?” This volume, a co-publication of the Society for Industrial BY THE NUMBERS Microbiology and Biotechnology and BioPlan Associates, Inc., provides an overview of the biopharmaceutical industry, ● 102 Internationally and the state of technology in China. Recognized Authors ● 21 Peer-Reviewers Readers will be able to: ● 1,139 Pages 1. Assess the state of biopharmaceutical development in China ● 70 Translated Chapters 2. Understand general business practices ● 5 Case Studies and China Briefs 3. Analyze business opportunities and identify potential partners ● 200+ Tables and Figures A peer-reviewed, ready reference for all aspects of ● 300+ References biopharmaceuticals in China, including an understanding of the ● Over 2,000 Index Entries China biopharma current situation, and future opportunities. Readers receive a comprehensive assessment of the state-of-the- This authoritative, peer-reviewed study industry, trends, and analysis. Information on all types of organizations is produced in collaboration with the involved in biopharma in China, whether they -
Supramolecular Aggregates As Sensory Ensembles
ChemComm View Article Online FEATURE ARTICLE View Journal | View Issue Supramolecular aggregates as sensory ensembles Cite this: Chem. Commun., 2016, Qian Wang,* Zhao Li, Dan-Dan Tao, Qian Zhang, Peng Zhang, Dai-Ping Guo and 52, 12929 Yun-Bao Jiang* As a new emerging area in chemical sensing, sensing using supramolecular aggregates exhibits unique advantages over that using conventional small-molecule chemical sensors, in terms of high sensitivity Received 22nd July 2016, and selectivity, and the simplicity of the sensory building blocks. This Feature Article outlines the recent Accepted 31st August 2016 research progress made in sensing based on induced supramolecular aggregation–disaggregation. The DOI: 10.1039/c6cc06075g reviewed sensory building blocks, in general, in the form of a small molecular sensor, yet with a much simpler structure, which form aggregates, are those of perylene derivatives, pyrene derivatives, tetra- www.rsc.org/chemcomm phenylethylene derivatives, metallophilic species and metal–organic frameworks. Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction in which four amino acid binding sites are covalently linked withinthesameEDTAframework,andthespecificbio- A molecular chemosensor in general consists of a molecular recognition which relies on multiple weak and less selective recognition site and a signal reporting group, which are either interactions operating in a cooperative manner, sensing using directly connected or linked by a spacer.1 In order to achieve aggregates that hold a more simply designed chemosensor(s) by high sensing performance, for instance, high sensitivity and noncovalent interactions was developed.2 Here the chemosensor- selectivity, the sensory molecule needs to be sophisticatedly like building block itself may exhibit less effective performance designed. -
How Scientist/Founders Lead Successful Biopharmaceutical
Antioch University AURA - Antioch University Repository and Archive Student & Alumni Scholarship, including Dissertations & Theses Dissertations & Theses 2008 How Scientist/Founders Lead Successful Biopharmaceutical Organizations: A Study of Three Companies Lynn Johnson Langer Antioch University - PhD Program in Leadership and Change Follow this and additional works at: http://aura.antioch.edu/etds Part of the Business Administration, Management, and Operations Commons, Medicine and Health Sciences Commons, and the Organizational Behavior and Theory Commons Recommended Citation Langer, Lynn Johnson, "How Scientist/Founders Lead Successful Biopharmaceutical Organizations: A Study of Three Companies" (2008). Dissertations & Theses. 138. http://aura.antioch.edu/etds/138 This Dissertation is brought to you for free and open access by the Student & Alumni Scholarship, including Dissertations & Theses at AURA - Antioch University Repository and Archive. It has been accepted for inclusion in Dissertations & Theses by an authorized administrator of AURA - Antioch University Repository and Archive. For more information, please contact [email protected], [email protected]. HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES Lynn Johnson Langer A DISSERTATION Submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May, 2008 This is to certify that the dissertation entitled: HOW SCIENTIST/FOUNDERS -
Nanotechnology Publications: Leading Countries and Blocs
Date: January 29, 2010 Author Note: I provide links and a copy of my working paper (that you may make freely available on your website) and a link to the published paper. Link to working paper: http://www.cherry.gatech.edu/PUBS/09/STIP_AN.pdf Link to published paper: http://www.springerlink.com/content/ag2m127l6615w023/ Page 1 of 1 Program on Nanotechnology Research and Innovation System Assessment Georgia Institute of Technology Active Nanotechnology: What Can We Expect? A Perspective for Policy from Bibliographical and Bibliometric Analysis Vrishali Subramanian Program in Science, Technology and Innovation Policy School of Public Policy and Enterprise Innovation Institute Georgia Institute of Technology Atlanta, GA 30332‐0345, USA March 2009 Acknowledgements: This research was undertaken at the Project on Emerging Nanotechnologies (PEN) and at Georgia Tech with support by the Project on Emerging Nanotechnologies (PEN) and Center for Nanotechnology in Society at Arizona State University ( sponsored by the National Science Foundation Award No. 0531194). The findings contained in this paper are those of the author and do not necessarily reflect the views of Project on Emerging Nanotechnologies (PEN) or the National Science Foundation. For additional details, see http://cns.asu.edu (CNS‐ASU) and http://www.nanopolicy.gatech.edu (Georgia Tech Program on Nanotechnology Research and Innovation Systems Assessment).The author wishes to thank Dave Rejeski, Andrew Maynard, Mihail Roco, Philip Shapira, Jan Youtie and Alan Porter. Executive Summary Over the past few years, policymakers have grappled with the challenge of regulating nanotechnology, whose novelty, complexity and rapid commercialization has highlighted the discrepancies of science and technology oversight.